Oct 17 (Reuters) - Molecular diagnostics firm

BillionToOne said on Friday it was aiming at a

valuation of up to $2.42 billion in its U.S. initial public

offering.

The Menlo Park, California-based company is looking to raise

up to $211.5 million in its IPO by offering 3.8 million shares

priced between $49 and $55 apiece.

The offering comes amidst a rebound in U.S. IPO activity,

reversing a slowdown from earlier this year, when trade-policy

uncertainty curbed momentum.

Despite the U.S. government shutdown, companies can tap a

provision that allows their registrations to become effective

automatically, which involves setting their IPO pricing 20 days

before the listing instead of finalizing it the night before.

BillionToOne develops molecular diagnostic tests - including

a non-invasive prenatal screen and liquid biopsy - for diseases.

The company filed for an IPO earlier this month and reported

revenue of $125.5 million in the first half of 2025, compared

with $69 million in the year-ago period.

The company will list on the Nasdaq under the "BLLN" ticker

symbol.

J.P. Morgan, Wells Fargo and William Blair are among the

underwriters for the offering.